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ABSTRACT 
T-regulatory cell 1 (Tr1) are low proliferating peripherally-induced suppressive T 
cells. Engaging CD3 and CD46 on human CD4
+
 T cells induces a Tr1-like phenotype. 
Here, we report that human Tr1-like cells do not sustain proliferation over time. The 
weak proliferation of these cells results first from their inability to sustain expression 
of various cell cycle-associated proteins, to efficiently degrade the inhibitor of cell 
cycle progression p27/Kip1, and, as a consequence, in their accumulation in the 
G0/G1 phase. Second, the reduced proliferation of Tr1-like cells results from their 
increased sensitivity to death as they divide, through a mechanism that is neither Fas-
mediated nor Bcl2/Bcl-xL-related. Both properties, impaired cell cycle and death 
sensitivity, are explained by a specific defective activation of Akt which impairs the 
expression of Survivin. Thus, our results show that CD3/CD46-induced Tr1-like cells 
die through a process of abortive proliferation. 
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INTRODUCTION 
Regulatory T cells are potent cells that inhibit self-antigen and innocuous-foreign 
antigen-specific adaptive immune effectors (1). Disrupting their functional activity 
often results in clinical pathologies. Moreover, pathogens and tumor cells can subvert 
immune responses by deviating regulatory T cells to their benefit (1, 2). Therefore, 
identifying what triggers the generation of regulatory T cells and understanding their 
biology appear to be required to struggle certain diseases and/or to efficiently use 
them as therapeutic tools (3). 
Among regulatory T cells, the peripherally-induced Tr1 cells were shown to control 
inflammation and allergy, to induce transplantation tolerance and to suppress immune 
responses to pathogens both in mice and humans (4-7). Tr1 cells are characterized by 
their production of IL-10 and IFN-?, their inability to secrete IL-2 and IL-4 and their 
poor proliferative potential (4). Tr1 cells were differentiated in vivo from mice 
injected with antigen-pulsed IL-10-treated DC (8) and in vitro from CD4
+
 T cells 
cultured with their cognate antigen in the presence of IL-10 both in mice and human 
(4).  Recently, it has been reported that the minimal engagement of the TCR and 
CD46 induces human CD4
+
 T cells with a Tr1-like phenotype, able to suppress T cell 
proliferation through the production of IL-10 (9). CD46 is a complement regulator 
that we initially described for its potential to co-stimulate T cells (10, 11). 
Nevertheless, unlike Tr1 cells, CD3/CD46-induced Tr1-like cells were described to 
exhibit a strong and prolonged proliferation (9). 
Using low concentration of anti-CD3 to better assess for the co-stimulatory role of 
CD46, we differentiated weakly proliferating human Tr1 cells. We report here that the 
poor proliferation of CD3/CD46-induced Tr1 cells results from a defect in cell cycle 
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progression and an increased sensitivity to cell death, both mechanisms being 
explained by a defective Akt pathway.  
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MATERIALS AND METHODS 
Cells and antibodies 
Human CD4
+
 T cells (>95% purity) were purified from blood donors (EFS Lyon, 
France) as described (10) and cultured in complete RPMI. For cell culture, the mAbs 
used were: anti-CD3, (OKT3, 1µg/ml, otherwise indicated); anti-CD46, (20.6, 
10µg/ml); anti-CD28, (CD28.2, 10µg/ml) (all Abs purified in our laboratory); anti-
CD95, (ZB4, 1?g/ml); isotype control (10µg/ml) (both from Beckman-Coulter 
Immunotech, Marseille, France). For FACS analysis, anti-CD25-PE, anti-CD69-FITC 
and anti-CD71-FITC were from Beckman-Coulter. For western blot, the Abs used 
were: anti-Survivin (D-8), and the rabbit polyclonal Abs specific for Akt, p27/Kip1, 
Cyclin A, Cyclin E and Cyclin-dependent-kinase-2 (Cdk2) (all from Santa Cruz 
Biotech. Inc., CA US); anti-Cyclin D1 (DCS6) and anti-phospho-Akt, (193H12) (both 
from Cell Signaling Technologies, Beverly, MA, US); anti-phospho-Erk1/2 (12D4) 
and the rabbit polyclonal Abs specific for Erk1/2 (both from Upstate Biotechnology, 
Lake Placid, NY) and anti-actin (Sigma-Aldrich, St Quentin Fallavier, France). 
 
Cell stimulation, proliferation and cytokine production analysis 
Naive CD4
+
 T cells were cultured on plates coated with the indicated mAbs, at a 
concentration of 1x10
6
 T cells/ml. When indicated, 10 U/ml of recombinant human 
IL-2 was added (a gift from Dr. Demetrier-Caux). 
3
H-Thymidine incorporation assays 
were as described (10). Cytokines were quantified from the supernatant of 3 days 
stimulated T cells by ELISA according to manufacturer’s instructions: IL-2, TNF-? 
and IL-8 (R&D Systems, Lille, France), IL-4, IL-5, INF-? and IL-13 (Pierce Perbio, 
Rockford, IL, US), IL-10 and TGF-? (Bender, Vienne, Austria). 
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Flow cytometry 
For cell death assessments, T cells were labeled with 67nM of ToPro-3 (Molecular 
Probes, Leiden, The Netherlands). To determine cell division numbers, 2x10
7 
T 
cells/mL (RPMI 2%FCS) were kept at 37°C for 13 min after addition of 0,5M CFSE 
(Molecular Probes), washed 3 times in cold RPMI 10%FCS and cultured for various 
periods of time before being analyzed by FACS. For cell cycle analysis, 0,5x10
6
 
CD4
+
 T cells were labeled 30min at room-temperature with 20?M 7-
Aminoactinomycin D (7-AAD) in 500?L of 0,03% saponin/NASS Buffer (100mM 
phosphate-citrate buffer pH=6, 150mM NaCl, 5mM EDTA, 0,5% BSA). Cells were 
kept on ice 5min and 5?M PY (Sigma) was added prior analysis. 
 
Western blot analysis 
T cells were lysed in ice-cold buffer, the protein concentration from each lysate 
determined (Micro-BCA kit, Pierce Perbio) and 50 µg of proteins were analyzed by 
SDS-PAGE
 
and Western blotting as described (11).  
 
Real-time RT-PCR 
One µg of mRNA was extracted from cultured T cells with Trizol (Invitrogen, 
Carlsbad, CA) and reverse transcribed into
 
cDNA using Superscript II reverse 
transcriptase (Invitrogen), 80pg of random hexamer primers (Promega, 
Charbonnières, France) and 150ng of oligo(dT)12-18 (Invitrogen). Real-Time PCR was 
performed with Platinium SYBR Green qPCR Supermix UDG (Invitrogen) on an 
Applied Biosystems GeneAmp 7600 thermocycler. The TATA-box Binding Protein 
(TBP) was used as housekeeping gene for mRNA normalization. The specificity of 
amplification was checked after each run and for each sample with a melting curve. 
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The TBP-specific primers were: F-5’-TGCTCATACCGTGCTGCTATCTG-3’ and 
R-5’-TTCTCCCTCAAACCAACTTGTCAAC-3’. Bcl-2 and Bcl-xL primers were a 
gift from Dr. N. Bonnefoy-Berard. Primers amplification efficiencies were 1.90 for 
TBP, 1.94 for Bcl-2 and 1.96 for Bcl-xL. 
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RESULTS AND DISCUSSION 
Weakly proliferating CD3/CD46-differentiated Tr1-like cells 
We previously reported that CD46 provides a co-stimulatory signal for human T cells 
(10). It was subsequently described that, in addition, CD46 favors the differentiation 
of human Tr1-like regulatory cells (9). To allow for an efficient assessment of the role 
of CD46 co-stimulation in Tr1 cell differentiation, we stimulated freshly purified 
naive human CD4
+
 T cells with an immobilized non-saturating concentration of anti-
CD3 (1?g/ml) in combination with anti-CD46 (Fig. 1A left panel). Such CD3/CD46-
stimulated T cells displayed a weak proliferation that was reminiscent to the Tr1 cell 
phenotype. On the contrary, as previously reported (9), higher concentrations of anti-
CD3 did allow for a more sustained proliferation of CD3/CD46-stimulated compared 
to CD3/CD28-stimulated (control effector) T cells (Fig. 1A). 
We then ensured that using a limiting concentration of anti-CD3 induced functional 
Tr1 cells. As shown in Fig. 1B low proliferating CD3/CD46-stimulated CD4
+
 T cells 
produced indeed the described phenotype of Tr1 cells (4, 9, 12). They produced IL-
10, IFN-? and IL-5, but neither IL-2 nor IL-4. However, they did not produce TGF-?, 
a cytokine produced at low levels when saturating concentrations of anti-CD3 were 
used (9). Moreover, low proliferating CD3/CD46-stimulated CD4
+
 T cells produced 
higher concentrations of IL-8 than CD3-stimulated CD4
+
 T cells (0.45 ± 0.07 ng/ml 
versus 0.19 ± 0.03 ng/ml, respectively), but equivalent IL-13 (0.4 ng/ml versus 
0,38ng/ml, respectively) and no significant levels of IL-6 and TNF-? were produced 
(data not shown. 
Finally the supernatant of weakly proliferating CD3/CD46-stimulated T cells 
efficiently suppressed the proliferation of CD3/CD28-stimulated CD4
+
 T cells in a 
dose dependant manner, whereas the supernatant of CD3-stimulated T cells did not 
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(Fig. 1C), confirming the regulatory phenotype of these cells. Altogether, these results 
clearly demonstrate that CD46 is a sufficient co-signal for the differentiation of 
weakly proliferating human suppressive Tr1 cells. 
 
Cell cycle defect of proliferating Tr1-like cells 
We reasoned as if the poor proliferation of Tr1-like cells could result from their 
inability to sustain cell division. A FACS analysis of CFSE-labeled stimulated naive 
CD4
+
 T cells revealed that both CD46 and CD28 co-stimulated T cells started to 
divide by day 3 with a similar kinetic (Fig. 2A). However, by day 5 of stimulation 
Tr1-like cells hardly performed more than 4 cycles of division (5% divided ?5 times) 
compared with control effector T cells (21% divided ?5 times) (Fig. 2A). 
The incompetence of Tr1-like cells to sustain cell division might result from a cell-
intrinsic deficiency in signal(s) controlling the progression of the cell cycle. 
Therefore, we analyzed the expression/down regulation of proteins associated with 
cell cycle in CD3/CD46-stimulated T cells. Three days post stimulation, CD3/CD46-
differentiated Tr1-like cells up-regulated the expression of the cyclins A, D1 and E 
and of Cdk2 to a similar extend than CD3/CD28-stimulated CD4
+
 T cells. However, 
by day 5, CD3/CD46-stimulated T cells failed to sustain the expression of the cyclins 
(Fig. 2B). 
We then examined the down regulation of the inhibitor of cell cycle progression 
p27/Kip1. Whereas CD28-co-stimulated T cells degraded p27/Kip1 as soon as day 1 
post activation and maintained such degradation up to day 5, CD46-co-stimulated T 
cells only partially down regulated p27/Kip1 mainly on day 3 (Fig. 2B). Since the 
degradation of p27/Kip1 is required for cells to progress from the G0/G1 phase to the 
S phase of the cell cycle (13), we wondered if CD3/CD46-stimulated T cells might 
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have a defect in cell cycle progression. Staining cells with 7-AAD and PY revealed 
that by day 3 of culture CD3/CD46-stimulated T cells accumulated in the G0/G1 
phase more abundantly than CD3/CD28-stimulated T cells (Fig. 2C). This result 
indicates that the lack of sustained proliferation of CD3/CD46-generated Tr1-like 
cells is due, at least partially, to a G0/G1 blockage in their cell cycle progression. 
 
Cell death sensitivity of dividing Tr1-like cells due to abortive proliferation 
In addition to a cell-intrinsic defect in cell cycle progression, the lack of sustained 
Tr1-like cell proliferation could result from an increased sensitivity of these cells to 
death. Therefore, we examined the survival of proliferating CD3/CD46-stimulated T 
cells by determining the rate of dead cells by ToPro-3 staining after 3, 4 and 5 days of 
culture. Until day 4, CD4
+
 T cells displayed comparable level of apoptosis whatever 
the nature of the stimulation, CD3, CD3/CD28 or CD3/CD46 (Fig. 3A). However, by 
day 5 more than 30% of the CD3/CD46-stimulated cells were apoptotic whereas less 
than 20% of cells in all other conditions of culture were ToPro-3
+
. We then asked if 
the sensitivity to death of Tr1-like cells correlated with their proliferation since Tr1 
are low proliferating cells. Indeed, the most the 5 days CD3/CD46-stimulated T cells 
divided, the most they underwent apoptosis with more than 40% of the cells that 
divided 5 times that were ToPro-3
+
 (Fig. 3B). On the contrary, whatever the number 
of division considered, we constantly observed about 20% of CD3/CD28-stimulated T 
cells that were ToPro-3
+
.  
Since Tr1-like cells do not produce IL-2, it was possible that CD3/CD46-stimulated T 
cells died because of the absence of a survival signal provided by IL-2. However, 
adding IL-2 to the CD3/CD46-stimulated T cell culture only marginally rescued 
differentiated Tr1-like cells from death (Fig. 3C). Therefore, the defective 
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proliferation of Tr1-like cells is due not only to a limited potential of proliferation but 
also to an increased sensitivity to cell death.  
Likewise, proliferating T cells may become sensitive to death through a Fas/FasL-
mediated mechanism (14). However, preventing the interaction between Fas and FasL 
with a blocking anti-Fas mAb did not rescue CD3/CD46-stimulated CD4
+
 T cells 
from death (Fig. 3D).  
Finally, the death of CD3/CD46-stimulated T cells could result from a defect of Bcl-2 
and/or Bcl-xL expression, two anti-apoptotic genes crucial for T cell survival (15). 
However, as revealed by real-time RT-PCR analysis from 3 days stimulated T cells, 
CD46 and CD28 co-stimulation up-regulated the expression of Bcl-xL mRNA to an 
equivalent extend, above the one observed from CD3-alone-stimulated T cells (Fig. 
3E). Moreover, the up-regulation of the Bcl-2 mRNA induced in CD3-stimulated T 
cells was neither impaired nor increased when cells were co-stimulated with either 
CD46 or CD28. Thus, proliferating Tr1-like cell death is not related to a defect of 
expression of either Bcl-2 or Bcl-xL. Altogether our results strongly suggest that the 
CD3/CD46-differentiated Tr1-like cells die because of an abortive proliferation 
mechanism. 
 
Defective expression of the Akt/Survivin pathway in Tr1-like cells 
The differences in terms of proliferation and survival between Tr1-like cells and 
effector T cells, evoked us that an important intracellular signaling pathway might be 
impaired in CD3/CD46-stimulated naive T cells. The PI(3)K/Akt pathway appeared 
to be a privileged target since Akt activation is crucial in CD28 co-stimulation 
dependant T cell proliferation and survival (16, 17). We looked for Akt activation by 
western blot using an activated-Akt specific mAb. Very interestingly, only marginal 
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activation of Akt was detected from lysate of T cells stimulated for 3 days with CD3 
and CD46 (Fig. 4A). On the contrary, as expected Akt was heavily activated in 3 days 
CD3/CD28-stimulated T cells and such activation was strongly maintained until day 
5. The defective Akt phosphorylation pathway in CD46-induced Tr1 cells was 
specific since the Erk1/2 MAPK pathway was equivalently phosphorylated from 3 
day CD3/CD46- and CD3/CD28-stimulated naive CD4
+
 T cells (Fig. 4A). Moreover, 
although the PI(3)K/Akt pathway was required for CD3/CD46-activated T cell 
proliferation, the sensitivity of such cells to PI(3)K-specific inhibitors, wortmannin 
and LY2940002 , was much more exacerbated compared to CD3/CD28-stimulated T 
cells and close to CD3-activated T cells, confirming the weak Akt activation in Tr1-
like cells (Fig. 4B and data not shown). On the contrary, CD3/CD46-stimulated CD4
+
 
T cells were as sensitive as CD3/CD28-stimulated CD4
+
 T cells towards the 
MEK/Erk1/2 specific inhibitor U0126 (Fig. 4C). 
In murine T cells, the activation of the Akt kinase regulates the expression of 
Survivin, a gene recently described to be crucial to maintain murine CD3/CD28-
stimulated CD4
+
 T cell division over time and to antagonize T cell apoptosis (18). We 
therefore assessed if an absence of Survivin expression might explain the sensitivity 
of the Tr1-like cells to death. First, we found that, as in mouse T cells, the co-
stimulation of human CD4
+
 T cells with CD3/CD28 did induce the expression of the 
Survivin protein by day 3 (Fig. 4D). Second, CD3/CD46-stimulated T cells did not up 
regulate the expression of Survivin over the level observed from CD3-stimulated T 
cells. Therefore, the impairment of CD46 to allow the induction of expression of 
Survivin probably explains why Trl-like cells have a limited proliferative potential 
and exhibit an increased potency to death. 
H
AL author m
anuscript    inserm
-00136616, version 1
The present work demonstrate that human CD3/CD46-induced Tr1 cells undergo 
abortive proliferation caused by a defect of cell cycle progression associated with a 
death of proliferating cells. The identification of a defective Akt pathway in human 
Tr1-like cells explain this particular phenotype and highlights several biological 
characteristics of these regulatory T cells. First, it explains why Tr1-like cells are 
incompetent at producing IL-2. This cytokine is produced by T cells when both Akt 
and ERK signaling pathways are activated (19), however we and others reported that 
the ERK pathway is fully activated in CD3/CD46-stimulated T cells (Fig. 4A, 11, 20). 
Second, the Akt pathway is required to optimally degrade p27/Kip1 (16), an 
inefficient event of Tr1-like cells, that is necessary for an efficient T cell proliferation. 
Third, the Akt pathway is crucial for the antigen-induced T cell survival and regulates 
the Survivin expression (17, 18), two processes that we show here to be defective in 
Tr1-like cells. Since Bcl-xL induction requires Akt activation it is possible that, in 
CD3/CD46-stimulated naive CD4
+
 T cells, the weak Akt activation is sufficient to 
induce Bcl-xL expression but not to sustain proliferation and Survivin expression. 
The nature of the signals involved in Tr1 differentiation in vivo still remains elusive 
and might be of circumstances. By engaging CD46, at least one self (complement C3b 
factor) and one nonself (streptococcal M protein) molecules have been shown to 
induce Tr1 cells (9, 21). Whatever the nature of the ligand engaging CD46 is, our 
results describe a mechanism that might be crucial to control the functional activity of 
the peripherally-CD46-induced Tr1 cells in order to limit bystander incongruous 
immunosuppression. Indeed, this control could be achieved by the elimination of 
activated Tr1 cells through a process of abortive proliferation. 
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FIGURE LEGENDS 
Figure 1: CD3/CD46 co-ligation induces weakly proliferating functional Tr1-like 
cells. (A) Naive human CD4
+
 T cells were stimulated with the indicated concentration 
of anti-CD3 mAbs alone or in combination with 10µg/ml of either anti-CD46 or anti-
CD28. T cell proliferation was measured by 
3
H-thymidine incorporation up to 5 days 
of culture. (B) CD4
+
 T cells were stimulated 3 days with anti-CD3 (1µg/ml) mAbs 
alone or in combination with 10µg/ml of either anti-CD46 or anti-CD28 and the 
culture supernatants were collected for cytokine quantification by ELISA. (C) CD4
+
 T 
cells were cultured with anti-CD3 (1µg/ml) + anti-CD28 (10µg/ml) mAbs in the 
presence of medium (?) or of serial dilutions of supernatants of 3 days CD3 (?) or 
CD3+CD46 (?) stimulated T cells. Proliferation was measured by 3H-thymidine 
incorporation after 3 days of culture. (** P<0,001 and * P<0,01). Results are 
representative of 2 (C) to 3 (A-B) independent experiments. When indicated, the ±SE 
is from means of triplicates of one out of 2 or 3 independent experiments. 
 
Figure 2: Accumulation of CD3/CD46-activated CD4
+
 T cells in the G0/G1 
phase. (A) CFSE-labeled naive human CD4
+
 T cells were activated as indicated and 
proliferation was analyzed by FACS at day 3, 4 and 5 of culture. (B) CD4
+
 T cells 
were activated with the indicated mAbs. At the mentioned time point, cells were lysed 
and 50µg of proteins for each condition were analyzed by SDS-PAGE
 
and western 
blotted for the indicated proteins. (C) CD4
+
 T cells were activated as indicated for 3 
days. Cells were then stained with 7-AAD and Pyronin Y (PY) and analyzed by 
FACS. Percentage of cells in each cell cycle phases is given. Results are 
representative of 3 independent experiments. 
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Figure 3: CD3/CD46 co-ligation induces abortive proliferation in CD4
+
 T cells. 
(A) Naive CD4
+
 T cells were stimulated as indicated for 3, 4 or 5 days, stained with 
ToPro-3 and the % of ToPro-3
+
 cells was determined by FACS. (B) CD4
+
 T cells 
were CFSE-labeled and activated as indicated. At day 5, cells were stained with 
ToPro-3 and analyzed by FACS to determine the % of ToPro-3
+
 cells according to the 
number of cell division. (C) Cells were analyzed as in (B) but 10U/ml of recombinant 
IL-2 was added during cultures. (D) CFSE-labeled CD4
+
 T cells were stimulated with 
the indicated mAbs in the presence or not of the blocking anti-Fas mAb ZB4. After 5 
days, cells were labeled with ToPro-3 to determine the % of dead cell per cell 
division. (E) CD4
+
 T cells were activated as indicated for 3 days before mRNA 
extraction. Bcl-2 or Bcl-xL mRNA expression was determined by real-time RT-PCR. 
The relative mRNA levels were normalized to the TATA box binding protein (TBP) 
gene. (** P<0,001 and * P<0,01). Results are representative of one out of three 
independent experiments. When indicated, the ±SE is from means of triplicates of one 
out of 3 independent experiments.  
 
Figure 4: Defective Akt activation and Survivin expression in CD3/CD46 co-
stimulated T cells. (A) Naive CD4
+
 T cells were activated up to 5 days as indicated. 
At each time point, cells were lysed and 50µg of proteins were analyzed as in Fig. 2B. 
Akt phosphorylation (p-Akt), Erk1/2 phosphorylation (p-Erk) and total Akt, Erk1/2 
and Actin were assessed by western blot. (B and C) CD4
+
 T cells were stimulated 
with the indicated mAbs in the presence of serial concentrations of Wortmannin (B) 
or  U0126 (C) and by day 3 T cell proliferation was measured by 
3
H-thymidine 
incorporation. For each point, the % of inhibition of proliferation was determined as 
follow: 100 - (cpm with inhibitor x 100 / cpm without inhibitor). (D) Survivin 
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expression was determined as in (A). Results are representative of 3 independent 
experiments. 
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